Xofluza generic
Xofluza is an antiviral drug owned by Genentech Inc. It contains the active ingredient baloxavir marboxil and was authorized for market use on 24 October, 2018. Xofluza has a total of 8 patents.
When will Xofluza generic be available?
The possibility of a Xofluza generic version being released is slated for after 25 September, 2038, which is the expiry date for the last patent on Xofluza. This possible release date is also contingent on whether any Para IV filings are submitted, challenging the drug patents, which could occur from 24 October, 2022 onwards.
Xofluza uses
Xofluza is used in the treatment and prevention of influenza. Its active ingredient, baloxavir marboxil, is used as a method for treating influenza, and also for post-exposure prophylaxis of influenza.
Xofluza patent expiration
Xofluza has a total of 8 patents, the last of which expires on 2038-09-25. These patents are a significant determinant for the release of Xofluza generic. Below are the details of the patents: